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OBJECTIVES The purpose of this study was to evaluate the efficacy and tolerability of monotherapy with the
selective aldosterone blocker eplerenone in both black and white patients with hypertension.
BACKGROUND Essential hypertension and cardiovascular-renal-target organ damage is more prevalent in
black than white adults in the U.S.
METHODS Black (n  348) and white (n  203) patients with mild-to-moderate hypertension were
randomized to double-blind treatment with eplerenone 50 mg, the angiotensin II receptor
antagonist losartan 50 mg, or placebo once daily. Doses were increased if blood pressure
remained uncontrolled. The primary end point was change in mean diastolic blood pressure
(DBP) after 16 weeks of therapy.
RESULTS Adjusted mean changes from baseline in DBP were 5.3  0.7, 10.3  0.7, and 6.9 
0.6 mm Hg in the placebo, eplerenone-treated, and losartan-treated groups, respectively
(mean  SE, p  0.001 eplerenone vs. placebo, p  0.001 eplerenone vs. losartan). In black
patients, DBP decreased by 4.8  1.0, 10.2  0.9, and 6.0  0.9 mm Hg for the
placebo, eplerenone-treated, and losartan-treated groups, respectively (mean  SE, p 
0.001 eplerenone vs. placebo, p  0.001 eplerenone vs. losartan), whereas in white patients,
DBP decreased by 6.4  1.0, 11.1  1.1, and 8.4  1.0 mm Hg, respectively (p 
0.001 eplerenone vs. placebo, p  0.068 for eplerenone vs. losartan). For reduction of systolic
blood pressure (SBP), eplerenone was superior to placebo and losartan in all patients
combined and in black patients, and was superior to placebo in white patients. Eplerenone
was as effective as losartan in reducing SBP and DBP in the high renin patient, but more
effective than losartan in the low renin patient. Similarly, eplerenone was at least as effective
as losartan in patients with differing baseline levels of aldosterone. Both eplerenone and
losartan were well tolerated.
CONCLUSIONS The antihypertensive effect of eplerenone was equal in black and white patients and was
superior to losartan in black patients. (J Am Coll Cardiol 2003;41:1148–55) © 2003 by the
American College of Cardiology Foundation
Hypertension and its complications cause significant and
excess morbidity and mortality in the general population
and particularly in black Americans (1). The age-adjusted
prevalence of hypertension is 40% higher in black versus
white Americans, onset is earlier, and the severity is greater
(2). Furthermore, the risk of death from hypertensive heart
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and renal disease is approximately twofold greater in black
Americans (1). The reason for these differences is unclear.
However, potential explanatory factors include increased
sodium sensitivity associated with low plasma renin activity
and obesity, and reduced potassium intake in black patients
(3,4).
Blood pressure (BP) control preserves target-organ func-
tion and minimizes risk for adverse clinical events (5). The
Sixth Report of the Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood
Pressure established the relatively conservative BP goal of
140/90 mm Hg for most patients, and the more stringent
goals of130/85 mm Hg for persons with diabetes mellitus
and125/75 mm Hg for patients with proteinuria in excess
of 1 g/day (5). However, only about 25% and 24% of black
and white hypertensive patients, respectively, achieve BP
140/90 mm Hg (2). At present, only 50% to 60% of all
patients can reach diastolic blood pressure (DBP) goals with
monotherapy (6), although responsiveness may be influ-
enced by race, age, pretreatment BP, geography, and kidney
function (7–11). For example, more white men than black
men 60 years reached the suggested DBP goal when
treated with an angiotensin-converting enzyme (ACE)
inhibitor (85% vs. 50%, respectively) (9). Lesser BP re-
sponses in black patients compared with white patients have
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also been observed with losartan, an angiotensin II receptor
antagonist (12). Although it is likely that racial differences
in BP responses are confounded, at least in part, by such
factors as the pretreatment BP level and the degree of
kidney dysfunction, it is important to determine both the
absolute and relative BP-lowering responses of black and
white patients.
Aldosterone receptor antagonists are logical therapeutic
options for the treatment of hypertension given that aldo-
sterone has a critical role in sodium homeostasis and plasma
volume regulation, and in mediating target-organ injury.
Spironolactone, a nonselective aldosterone blocker, lowers
BP in patients with essential hypertension and reduces
morbidity and mortality in patients with severe heart failure
(13,14). However, chronic spironolactone use is limited
owing to its interactions with progesterone and androgen
receptors which can result in gynecomastia, breast tender-
ness, menstrual abnormalities, and impotence (13–15).
Eplerenone, the first selective aldosterone blocker (SAB),
is being developed for the treatment of hypertension and
congestive heart failure. Studies in hypertensive animal
models showed that eplerenone reduces both myocardial
necrosis and renal arteriopathy (16). Due to highly selective
receptor binding, it is expected that eplerenone will be more
tolerable than spironolactone. We conducted a randomized,
double-blind study to determine the efficacy and tolerability
of monotherapy with eplerenone compared with losartan
and placebo in black and white patients with mild-to-
moderate hypertension.
METHODS
Study population. Men and women 18 years old with
mild-to-moderate hypertension were eligible for inclusion if
their systolic blood pressure (SBP) was 180 mm Hg and
DBP was 95 to 109 mm Hg without medication. Only
patients self-identified as black or white were included.
Patients on one or two antihypertensive medications were
eligible only if their BP was 140/90 mm Hg. Patients
were excluded if they had known secondary hypertension,
insulin-dependent diabetes mellitus, hepatic disease, or
elevated serum creatinine level; evidence of alcohol or drug
abuse; could not be withdrawn from antihypertensives; or
regularly used corticosteroids. Patients with a history of
New York Heart Association functional class II to IV
congestive heart failure, myocardial infarction, coronary
revascularization, stroke, or transient ischemic attack within
the past six months, current unstable angina, or any serious
medical condition were also excluded. The protocol was
approved by the institutional review board at each study site.
All patients provided written informed consent.
Study design. This was a randomized, double-blind,
placebo- and active-controlled, placebo run-in, parallel
group trial conducted at eight centers in South Africa and
42 centers in the U.S. between January 4, 2000 and January
19, 2001. The study population was stratified at a 2:1 ratio
of black to white patients. The primary study end point was
the mean change in DBP from baseline to the final visit.
Secondary end points were the mean change from baseline
to the final visit for SBP and DBP within and between racial
groups; improvement in urinary protein excretion as mea-
sured by changes in the urinary albumin/creatinine ratio
(UA/CR); and the effect of eplerenone in selected subpopu-
lations, including women, obese patients, patients with SBP
160 mm Hg, elderly patients, and patients with mi-
croalbuminuria. Exploratory analyses assessed the rate of
response to therapy and the relationships between BP
changes and baseline active renin or aldosterone levels.
Study procedures. At a screening visit, patients underwent
a complete physical examination, including medical history,
12-lead electrocardiogram, heart rate (HR) and BP (by cuff
sphygmomanometer), and laboratory testing. Patients suc-
cessfully withdrawn from antihypertensive medication,
without arrhythmia requiring treatment, without clinically
significant laboratory abnormality, and with a serum potas-
sium level of 3.5 to 5.0 mmol/l, were entered into a two- to
four-week, single-blind, placebo run-in period.
At the end of the placebo run-in period, eligible patients
(mean cuff DBP 95 mm Hg and 110 mm Hg and a
mean cuff SBP 180 mm Hg, negative urine and serum
pregnancy tests, medication compliance during placebo
run-in) were randomized (stratified by race) to treatment
with eplerenone, losartan, or matching placebo. Treatment
was initiated with daily doses of eplerenone 50 mg, losartan
50 mg, or matching placebo administered in the morning. If
DBP was 90 mm Hg or SBP was 140 mm Hg at weeks
4, 8, or 12, the dose was increased to 100 mg/day of
eplerenone or losartan. If BP remained 140/90 mm Hg,
the dose was increased to eplerenone 200 mg/day or
continued at losartan 100 mg/day, the maximal recom-
mended dose. Patients were withdrawn from the study for
the following reasons: if DBP was95 mm Hg or SBP was
150 mm Hg after week 12 at the highest dose of study
drug; if DBP was 110 mm Hg or SBP was 180 mm Hg
at two consecutive visits taking place 1 to 3 days apart; if
symptomatic hypotension (lightheadedness, dizziness, or
syncope) occurred; or if serum potassium level was 5.5
mmol/l on two consecutive measurements done 1 to 3 days
apart.
Randomized patients were assessed every two weeks for
HR, BP, serum potassium level, and adverse events. Active
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANCOVA  analysis of covariance
BP  blood pressure
CI  confidence interval
DBP  diastolic blood pressure
HR  heart rate
SAB  selective aldosterone blocker
SBP  systolic blood pressure
UA/CR  urinary albumin/creatinine ratio
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renin and serum aldosterone quantitation was performed at
week 0 and final visit. To do so, blood samples were
collected by direct venipuncture from patients in the seated
position, and plasma was separated by centrifugation. Levels
of active renin and aldosterone were determined by radio-
immunoassay using kits from Nichols Institute Diagnostics
and Abbott Laboratories, respectively. Hematologic and
biochemical analysis and urinalysis were performed at week
0 and the final visit. A first morning voided spot urine
specimen was used for assessment of UA/CR at week 0 and
the final visit.
Statistical analysis. A priori power calculations deter-
mined the sample size of black and white patients that was
required to detect a 4.5 mm Hg difference in DBP from
baseline between eplerenone and placebo with power of
99%, 97%, and 80%, respectively, in all patients, black
patients, and white patients. The study also had a power of
90% for all patients and 75% for black patients to show a 3
mm Hg difference in DBP between the eplerenone and
losartan groups.
Analyses were performed in all patients combined,
within, and between racial groups. All randomized patients
with a baseline BP assessment and 1 post-baseline assess-
ment were included in the intent-to-treat analysis. Missing
values were imputed using the last observation carried
forward method.
Baseline factors for treatment groups were compared
using one-way analysis of variance for continuous variables
or Pearson chi-square tests for categorical variables. The BP
measurement obtained on the last visit of the placebo run-in
period was the baseline value, and the last BP measurement
during the 16-week treatment period was the final value. BP
data were analyzed using two-way analysis of covariance
(ANCOVA) with the baseline measurement as the covari-
ate and treatment and center as factors. Analyses of BP
differences between racial groups used a similar model,
adding race as a factor. The significance of response rates
was determined using the Cochrane-Mantel-Haenszel test.
The ANCOVA analysis was used in exploratory analyses.
Results for treatment effect comparisons in all patients and
in black and white patients, including mean changes from
baseline in SBP/DBP at week 16 end point as well as weekly
changes, are based on adjusted means (adjusted for baseline
value, treatment, and center) from the ANCOVA model.
The results from the subgroup analysis (based on the tertile
of baseline aldosterone and active renin) are derived from
the raw mean changes and two-sample test between the raw
mean changes within each subgroup. In the safety analysis,
the incidences of adverse events are summarized and com-
pared using Fisher exact test. A two-tailed p value of 0.05
was considered statistically significant.
RESULTS
Patient characteristics. A total of 551 patients were ran-
domized to study treatment, and 352 completed 16 weeks of
treatment. Of these, 16 patients (4 placebo, 8 eplerenone,
and 4 losartan) had no post-baseline assessment; therefore,
535 patients were included in the cohort for efficacy analysis
(Table 1). Compliance, determined by patient diary and
counting of patients’ returned medication by study person-
nel at each clinic visit, was 90.5% in the placebo group,
91.5% in the eplerenone group, and 88.6% to 89.1% in the
losartan group. No significant differences were observed
between the three randomized treatment groups for baseline
demographic or clinical characteristics (Table 2). As ex-
pected, however, there was a difference in active renin
concentration between black and white patients (data not
shown). Thus, in black (n  243) versus white (n  156)
patients, active renin was 10.3 mU/l versus 13.8 mU/l,
respectively (p  0.001). Serum aldosterone was similar in
black and white patients (6.8 vs. 7.4 ng/dl, respectively, p 
0.25).
Efficacy. Mean changes in DBP and SBP from baseline to
final visit (week 16) were significantly greater with
eplerenone treatment than with placebo or losartan treat-
ment in all patients combined (p  0.001) and in black
patients (p  0.001) (Table 3). Among white patients,
adjusted mean changes in DBP and SBP were significantly
greater with eplerenone treatment than with placebo (p 
0.001), but not significantly different between eplerenone
and losartan, although the change in DBP approached
significance (p 0.068) (Table 3). Significant differences in
DBP between eplerenone and placebo or losartan were
observed by week 4 in black patients and were maintained
for the study duration (Fig. 1). Response rates (defined as
the percentage of patients with DBP 90 mm Hg or with
DBP 90 mm Hg but 10 mm Hg below baseline) for
placebo, eplerenone, and losartan were 41.2%, 64.5%, and
48.3%, respectively (p  0.001 for eplerenone vs. placebo,
p  0.003 for eplerenone vs. losartan).
The change from baseline in the UA/CR was determined
Table 1. Patient Disposition
Placebo
No. (%)
Eplerenone
No. (%)
Losartan
No. (%)
Randomized 181 182 188
Intent-to-treat population 177 174 184
Completed 107 (59.1) 134 (73.6) 111 (59.0)
Withdrawn 74 (40.9) 48 (26.4) 77 (41.0)
Lost to follow-up 7 (3.9) 8 (4.4) 9 (4.8)
Preexisting violation 0 0 2 (1.1)
Noncompliance 6 (3.3) 1 (0.5) 6 (3.2)
Treatment failure 45 (24.9) 20 (11.0) 43 (22.9)
Adverse event 6 (3.3) 6 (3.3) 8 (4.3)
Increased potassium level* 0 1 (0.5) 0
Other 10 (5.5) 12 (6.6) 9 (4.8)
Final dose level (n)
Dose level 1 31 (19) 45 (26) 43 (24)
Dose level 2 31 (19) 52 (30) 34 (19)
Dose level 3 103 (62) 75 (44) 101 (57)
*5.5 mmol/l K on two occasions one to three days apart. Dose level 1: eplerenone
50 mg QD or losartan 50 mg QD; Dose level 2: eplerenone 100 mg QD or losartan
100 mg QD; Dose level 3: eplerenone 200 mg QD or losartan 100 mg QD.
QD  every day.
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in a partial patient sample (n  118, 132, and 133 for
placebo, eplerenone, and losartan, respectively). This anal-
ysis covered a smaller population because urine samples were
not available for a number of patients at baseline and/or the
final visit. The calculated mean percent change was 5.2%
(95% confidence interval [CI] 8.4 to 20.8) for placebo,
21.6% (95% CI 31.3 to 10.7) for eplerenone, and
18.2% (95% CI 28.3 to 6.7) for losartan, indicating
improvement from both treatments compared with placebo
(p  0.003 for eplerenone vs. placebo). There was no
difference in UA/CR change between the eplerenone and
losartan groups (p  0.652).
Analysis of special patient populations. Subgroup analy-
sis failed to show any significant differences in efficacy for
eplerenone in women, men, and patients with baseline SBP
160 mm Hg (Table 4). Eplerenone was also effective in
both obese and nonobese patients (data not shown).
Eplerenone was more effective than losartan in lowering
SBP and DBP in the moderate and low renin patient, and
was as effective as losartan in the high renin patient (Fig. 2).
Similarly, eplerenone was more effective in reducing SBP
than losartan in patients with low and high aldosterone
levels, and was more effective in reducing DBP in patients
with low aldosterone levels (Fig. 3). Eplerenone was similar
to losartan in antihypertensive effect at all other baseline
aldosterone levels.
Tolerability. Six (3.3%) patients in the placebo and
eplerenone groups and eight (4.3%) in the losartan group
discontinued study medication for adverse events. Adverse
events were reported by 85, 89, and 81 patients in the
placebo, eplerenone, and losartan groups, respectively (Ta-
ble 5). Most frequently reported events included headache,
respiratory system disorders, and gastrointestinal disorders.
No significant differences in the incidence of adverse events
were noted between eplerenone and placebo or losartan
(Table 5). No patient in the eplerenone treatment group
reported impotence, gynecomastia, or breast tenderness; two
patients reported menstrual disorder; and two reported
decreased libido (Table 5).
Vital signs and laboratory values were very similar among
patients treated with placebo, eplerenone, and losartan. No
significant differences versus baseline in adjusted mean HR
were observed between treatment groups for all patients. No
clinically significant differences between eplerenone and
Table 2. Baseline Demographic Characteristics and Selected Clinical Values
Characteristic
Placebo
(n  181)
Eplerenone
(n  182)
Losartan
(n  188)
Female (%) 97 (53.6) 117 (64.3) 105 (55.9)
Age (yrs) 52.1  11.1 50.9  11.2 52.0  10.3
Black (%) 113 (62.4) 115 (63.2) 120 (63.8)
Weight female (kg) (mean  SD) 83.9  18.9 86.5  18.5 89.6  21.4
Weight male (kg) (mean  SD) 93.2  16.9 92.7  17.4 94.8  18.0
Seated pressure (mm Hg) n  177 n  174 n  184
SBP (mean  SD) 148.9  11.6 149.3  11.3 150.7  11.6
DBP (mean  SD) 99.1  3.6 98.9  3.5 99.2  3.5
HR (beats/min) (mean  SD) 73.1  8.9 73.6  8.3 71.5  8.8
UA/CR (g/mmol)
(geometric mean)
n  118 n  132 n  133
991 941 1,049
RAAS profile n  121 n  137 n  141
Active renin (mU/l) (geometric mean) 12.0 11.3 11.3
Serum aldosterone (ng/dl) (geometric mean) 7.5* 7.0 6.7*
*n  120 for placebo, n  140 for losartan.
DBP  diastolic blood pressure; HR  heart rate; RAAS  renin-angiotensin-aldosterone system; SBP  systolic blood
pressure; UA/CR  urinary albumin/creatinine ratio.
Table 3. Mean Changes in SBP and DBP for Placebo, Eplerenone, and Losartan at End Point
(Week 16)
Variable Placebo Eplerenone Losartan
p Values*
Eplerenone vs.
Placebo
Eplerenone vs.
Losartan
All patients n  177 n  174 n  184
SBP 3.4  1.05 12.8  1.06 6.3  1.04  0.001  0.001
DBP 5.3  0.65 10.3  0.66 6.9  0.64  0.001  0.001
Black n  110 n  108 n  117
SBP 3.7  1.48 13.5  1.43 5.3  1.43  0.001  0.001
DBP 4.8  0.96 10.2  0.94 6.0  0.94  0.001 0.001
White n  67 n  66 n  67
SBP 3.2  1.78 12.3  1.79 8.5  1.76 0.001 0.126
DBP 6.4  1.04 11.1  1.05 8.4  1.03 0.001 0.068
*Analysis of variance with treatment and center as factors and baseline value as covariate.
DBP  diastolic blood pressure; SBP  systolic blood pressure.
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Figure 1. Mean change from baseline for diastolic blood pressure (DBP) in (A) black patients and (B) white patients. Diamonds  placebo; squares 
eplerenone; triangles  losartan. *p  0.05, **p  0.01, ***p  0.001 for eplerenone versus placebo or losartan.
Table 4. Mean Changes in SBP and DBP in Special Patient Populations at End Point
(Week 16)
Population Placebo Eplerenone Losartan
p Values
Eplerenone
vs. Placebo
Eplerenone
vs. Losartan
Women n  97 n  114 n  105
SBP 5.3  1.4 14.8  1.3 6.8  1.4  0.001  0.001
DBP 6.5  0.9 11.8  0.8 7.4  0.8  0.001  0.001
Men n  80 n  60 n  79
SBP 1.6  1.5 8.7  1.8 5.4  1.5 0.002 0.16
DBP 4.2  1.0 7.4  1.2 5.8  1.0 0.04 0.32
Patients with high baseline SBP* n  33 n  30 n  43
SBP 7.2  3.1 22.8  3.2 8.1  2.7 0.001 0.001
DBP 1.8  1.9 11.6  2.0 5.1  1.6 0.001 0.013
*Baseline SBP 160 mm Hg.
Abbreviations as in Table 3.
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placebo or losartan were observed for liver function tests,
serum creatinine, or blood urea nitrogen. At the final visit,
mean changes in serum uric acid levels were 2.4  4.6, 13.0
 4.3, and15.1 3.6 mol/l for the placebo, eplerenone,
and losartan groups, respectively (p  0.001 for eplerenone
vs. losartan); all changes were within the normal range.
Similarly, changes in serum potassium at study end were
0.01 0.03,0.09 0.03, and0.03 0.03 mmol/l in
the placebo, eplerenone, and losartan groups, respectively
(p  0.001 for eplerenone vs. placebo, p  0.003 for
eplerenone vs. losartan). A serum potassium level 5.5
mmol/l was observed for three, four, and three patients in
the placebo, eplerenone, and losartan groups, respectively.
One eplerenone-treated patient was withdrawn due to an
elevated potassium level.
More patients discontinued therapy in the placebo and
losartan groups than in the eplerenone group, primarily
because of treatment failure (p  0.0001 for eplerenone vs.
placebo, p  0.001 for eplerenone vs. losartan [Table 1]).
Figure 2. Changes in systolic blood pressure (SBP) and diastolic blood
pressure (DBP) associated with treatment according to baseline level of
active renin. *p  0.001 versus placebo and losartan; †p  0.01 versus
placebo and losartan; ‡p 0.03 versus placebo; §p 0.002 versus placebo.
White bars8.2 mU/l; lined bars8.2 and13.4 mU/l; black bars
 13.4 mU/l.
Figure 3. Changes in systolic blood pressure (SBP) and diastolic blood
pressure (DBP) associated with treatment according to baseline aldosterone
level. *p  0.03 versus placebo and losartan; †p  0.001 versus placebo; ‡p
 0.005 versus placebo and losartan; §p 0.001 versus placebo, p 0.033
versus losartan. White bars  5.6 ng/dl; lined bars  5.6 and 9.6
ng/dl; black bars  9.6 ng/dl.
Table 5. Incidence of Adverse Events
Adverse Events
Placebo
n  181
No. (%)
Eplerenone
n  182
No. (%)
Losartan
n  188
No. (%)
Any event 85 (47.0) 89 (48.9) 81 (43.1)
Headache 26 (14.4) 25 (13.7) 24 (12.8)
Respiratory system disorders 21 (11.6)* 35 (19.2)† 29 (15.4)
Gastrointestinal disorders 16 (8.8) 19 (10.4) 11 (5.9)
Musculoskeletal system disorders 7 (3.9) 4 (2.2) 10 (5.3)
Psychiatric disorders 4 (2.2) 7 (3.8) 3 (1.6)
Dizziness 5 (2.8) 8 (4.4)† 2 (1.1)
Hyperkalemia 1 (0.6) 2 (1.1) 0
Hypokalemia 1 (0.6) 0 1 (0.5)
Increased liver enzymes 2 (1.1) 0 2 (1.1)
Menstrual disorder (women) 0 2 (1.7) 1 (1.0)
n  97 n  117 n  105
Impotence (men) 1 (1.2) 0 1 (1.2)
n  84 n  65 n  83
Libido decreased 0 2 (3.1) 0
*p  0.10 between eplerenone and placebo. †p  0.10 between eplerenone and
losartan. No significant differences between eplerenone and placebo were observed.
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Treatment failure was lowered significantly in black
eplerenone-treated patients compared with placebo (12/115
[10.4%] vs. 29/113 [25.7%], respectively [p  0.003]) and
trended towards a decrease in white patients treated with
eplerenone (8/67 [11.9%] vs. 16/68 [23.5%], eplerenone vs.
placebo [p  0.078]).
DISCUSSION
This study demonstrated that eplerenone treatment signif-
icantly reduced DBP and SBP compared with placebo in
both black and white patients with mild-to-moderate hy-
pertension. Eplerenone monotherapy was more effective
than losartan monotherapy for all patients combined and in
black patients, and was comparable to losartan in white
patients. It should be pointed out that use of the term “all
patients combined” in this analysis is influenced by the
preponderantly black population (63% black vs. 37% white);
thus, the increased efficacy seen in blacks influenced the
improved efficacy seen in “all patients combined.” Never-
theless, within both racial groups, the estimated mean
change in DBP and SBP consistently rank-ordered
eplerenone  losartan  placebo.
Previous studies have suggested that racial differences in
response to hypertension therapy are drug-class specific.
Monotherapy with angiotensin II receptor antagonists
lower BP less in black than in white patients (12,17); these
findings were confirmed by our study. Similarly, black
hypertensive patients do not respond as well as white
patients to lower doses of ACE inhibitor or beta-blocker
monotherapy, although uptitration to higher doses of ACE
inhibitors either eliminates or narrows any racial difference
in BP-lowering efficacy (18–20). However, black patients
have been found to respond better to thiazide diuretics and
calcium channel blockers than white patients (7,9,19). In
this study, antihypertensive treatment with monotherapy
using eplerenone, the SAB, is similarly effective in both
black and white patients.
Predicting the most effective hypertension monotherapy
in a given patient can be challenging. A crossover study
rotating treatment among an ACE inhibitor, a beta-
blocker, a calcium channel blocker, and a diuretic indicated
that patients respond either to the first two drugs or to the
latter two (21). Another study predicted medication re-
sponse based on age-race subgroup or renin profile (9). Our
exploratory analyses suggest that many patient populations
respond consistently to eplerenone (black patients, white
patients, men, women, obese patients, nonobese patients,
patients with SBP 160 mm Hg, and patients with low
renin activity), which may increase the likelihood of treat-
ment success. Indeed, observation of overall treatment
failure was 11.0% with eplerenone, compared with 24.9%
and 22.9% with placebo and losartan, respectively (Table 1).
A recent study demonstrated that the majority of patients
with uncontrolled BP have SBP levels higher than goal (22).
In this present study, the maximal decrease in SBP (22.8
mm Hg) was demonstrated in eplerenone-treated patients
with SBP 160 mm Hg (Table 4). Therefore, eplerenone
treatment may be a highly effective therapeutic option for
patients with prominent SBP elevations.
An important goal of hypertensive therapy is to prevent
complications, including kidney and cardiovascular damage.
Inhibiting the actions of either angiotensin II or aldosterone
protects against target organ damage in rat models of
hypertension (16,23,24). The UA/CR reflects the degree of
albuminuria, which is predictive of both renal damage (25)
and cardiovascular events (26). Both eplerenone and losar-
tan significantly reduced the UA/CR relative to placebo,
and therefore may reduce the risk for complications of
hypertension.
No significant differences in adverse events incidence or
type were observed between eplerenone or losartan or
placebo. A non-significant trend towards increased respira-
tory disorders was observed in patients treated with
eplerenone (Table 5). The reported incidence of gynecom-
astia, breast pain, menstrual abnormalities, impotence, and
decreased libido with eplerenone was low and comparable to
losartan and placebo. These adverse events have been
reported much more frequently with spironolactone treat-
ment 50 mg/day for 23 months (13–15). Further, no
clinically relevant differences in laboratory test results were
observed between eplerenone and placebo. Small increases
in serum uric acid and serum potassium concentration in the
eplerenone group were within the normal range and without
clinical consequence.
This study indicates that eplerenone, a novel antihyper-
tensive agent, significantly reduces DBP and SBP in both
black and white patients and is well tolerated. Eplerenone
appears to effectively lower BP across a broad spectrum of
patients, including those with low active renin levels and,
therefore, may protect patients from hypertension-related
target-organ damage.
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